Title: Study on Cystatin C as an Early Biomarker of Nephropathy in Patients with Type-2 Diabetes

Authors: Dr Sanjiv Kumar, Dr Mohd Shafat Imam Siddiqui, Dr Nikhil Sinha

 DOI:  http://dx.doi.org/10.18535/jmscr/v4i1.32

Abstract

Diabetes mellitus (DM) is a syndrome associated with chronic hyperglycemia due to relative insulin deficiency, resistance, or both. Our aim to evaluate the clinical usefulness of cystatin C levels in the serum in predicting renal impairment in patients with type 2 diabetes. Thus, we explored the possibility of the cystatin C levels of serum and urine as markers of early renal impairment in normoalbuminuric patients with diabetes. We also evaluated the relationship of albuminuria and serum/urine cystatin C.

Keywords: Cystatin C, Diabetic Nephropathies and Albuminuria.

References

1.      MK Yadav, Dr TK Mohapatra, Dr TK Mohapatra et. al. Study on Glycated Hemoglobin & lipid profile in Type-2 Diabetes Mellitus. International Journal of Science & Research (IJSR) 2015;4(6): 1917-19.

2.      Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.

3.      Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, Narayan KM, Williamson DF. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005;293: 1868-74.

4.      Olivarius Nde F, Andreasen AH, Keiding N, Mogensen CE. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study “diabetes care in general practice”, Denmark. Diabetologia 1993; 36:1007-16.

5.      Comper WD, Osicka TM, Jerums G. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis 2003;41: 336-42.

6.      Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61: 1453-61.

7.      Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, Miccoli R, Del Prato S, Penno G. Cystatin C and estimates of renal function:searching for a better measure of kidney function in diabetic patients.Clin Chem 2007; 53: 480-8.

8.      Rigalleau V, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, Raffaitin C, Perlemoine C, Barthe N, Combe C, Gin H. Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab 2008; 34:482-9.

9.      Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis 2001; 38: 310-6.

10.  Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005; 38:1–8.

11.  Haase-Fielitz A1, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery — a prospective cohort study. Crit Care Med. 2009;37:553–60.

12.  Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, et al.Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 2000; 20:97–102.

13.  Hilpak M, Katz R, Sarnak M, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons with chronic kidney disease. Ann Intern Med 2006; 145:237–246.

14.  Andreoli TE, Benjamin I, Griggs R, Wing E, Fitz JG. Cecil Essentials of medicine 8th edition. Chronic renal failure, 2010. Elsevier, Philadelphia, USA. Elsevier Saundersp. 369.

15.  Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65:1416.

16.  Kumar P, Clark M. Clinical medicine 7th edition. Diabetes mellitus, Elsevier, Philadelphia, USA 1029-1053, 2009 Elsevier Saunders.

17.  Larson A, Malm J, Grubb A, Hanson LO. Calculation of glomerular filtration rate express in ml/min from plasma cyctatin C values in mg/l. Scand J Clin Lab Invest 2004; 64:25–30.

18.  Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52:1036–1040.

19.  Lodin M, Hansson L, Larsson A. Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls. Clin Chem Lab Med 2006; 44:1481–1485.

20.  SA Sheikh, JA Baig, T Iqbal, T Kazmi, M Baig, SS Husain. Prevalence of microalbuminuria with relation to glycemic control in type-2 diabetic patients in Karachi. Elsevier, Philadelphia, USA, J Ayub Med Coll Abbottabad 2009; 21:83–86.

21.  Thomas L, Huber AR. Renal function — estimation of glomerular filtration rate. Clin Chem Lab Med 2006; 44:1295, 1302.

22.  YK Jeon, MR Kim, JE Huh, JY Mok, SH Song, SS Kim, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011; 26:258–263.

23.  Hergert-Rothenthal S, Trabold SI, Pietruck F, et al. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 2000; 20:97–102.

Corresponding Author

Dr Sanjiv Kumar

MBBS, MD, Assistant Professor, Department of Medicine

Heritage Institute of Medical Sciences, Varanasi-221311, Uttar Pradesh, India